IMODIUM MULTI-SYMPTOM RELIEF OTC
Generic Name and Formulations:
Loperamide HCl 2mg, simethicone 125mg; chew tabs; caplets; mint flavored; contains calcium.
McNeil Consumer Healthcare
Indications for IMODIUM MULTI-SYMPTOM RELIEF:
Diarrhea with gas.
Chew tabs: take with 4–8oz of water after each dose. Initially 2 chew tabs or caplets, then 1 chew tab or caplet after each loose stool; max 4 tabs or caplets per day for 2 days.
<6yrs: consult physician. Chew tabs: take with 4–8oz of water after each dose. ≥6yrs: initially 1 chew tab or caplet, then ½ chew tab or caplet after each loose stool. 48–59lbs (6–8yrs): max 2 tabs or caplets per day for 2 days. 60–95lbs (9–11yrs): max 3 tabs or caplets per day for 2 days.
If constipation must be avoided. Acute dysentery.
Acute ulcerative colitis and antibiotic induced pseudomembranous colitis; discontinue if abdominal distention occurs. In dehydration, use fluid and electrolyte replacement. Hepatic dysfunction; monitor for CNS toxicity. Pregnancy (Cat.B). Nursing mothers.
Antidiarrheal + antiflatulent.
Abdominal pain, distention, constipation, dry mouth, nausea, drowsiness, dizziness, fatigue, rash.
Caps—30; A-D Caplets—6, 12, 18, 24; A-D Liq—2oz, 4oz; Multi-Symptom Caplets—12, 42; Multi-Symptom Chew tabs—18, 42
Clinical Pain Advisor Articles
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness